Takeda ’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
Osaka, Japan - January 29, 2018 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAK-426, Takeda’s purified, inactivated,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 29, 2018 Category: Pharmaceuticals Source Type: clinical trials
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
Osaka, Japan, November 28, 2017 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) today announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into a Phase 1... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2017 Category: Pharmaceuticals Source Type: clinical trials
Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants
Conditions: Virus, Zika; Zika Virus Disease; Flavivirus Infections; Healthy Participants Interventions: Drug: Placebo; Biological: PIZV Sponsor: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2017 Category: Research Source Type: clinical trials
